Ilkka Oyj
26.3.2026 18:00:00 CET | Globenewswire | Press release
Ilkka Oyj: Acquisition of own shares on 26 March 2026
Ilkka Oyj: Acquisition of own shares on 26 March 2026
Ilkka Oyj Stock Exchange Release 26 March 2026, at 07:00 p.m. EET
Ilkka Oyj: Acquisition of own shares on 26 March 2026
| Date | 26 March 2026 | |
| Exchange transaction | Buy | |
| Share trading code | ILKKA2 | |
| Amount, shares | 2,100 | |
| Average price/share (EUR) | 4.2390 | |
| Total cost (EUR) | 8,901.90 |
After the acquisitions Ilkka Oyj holds a total of 138,561 treasury shares (ILKKA2).
On behalf of Ilkka Oyj
Danske Bank A/S, Finland Branch
Antti Väliaho Jonathan Nyberg
For more information, please contact:
Olli Pirhonen, CEO, Ilkka Oyj
olli.pirhonen@ilkka.com
DISTRIBUTION
Nasdaq Helsinki
Main media
www.ilkka.com
Ilkka Oyj in brief
Ilkka is a marketing and technology company that offers professional, data and technology services in digital marketing and communications. The core of Ilkka's business is formed by the software company Liana, a pioneer in marketing and communication technology, and its Swedish subsidiary Ungapped; the leading expert in data-driven sales and marketing, Profinder; Finland's leading WordPress digital agency Evermade; Finland's leading social media marketing expert agency MySome; and the strategic B2B marketing partner Myynninmaailma. Our success relies heavily on knowing the entire purchase path and utilizing modern technology, data, and AI. Our international focus is particularly on Sweden and the emerging markets in the Middle East. The group's services are provided by approximately 330 marketing, technology, and data experts.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom